Modality
Small Molecule
MOA
TYK2i
Target
TIGIT
Pathway
Notch
RSVCKDObesity
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
~Apr 2018
→ ~Jul 2019
Phase 3
Oct 2019
→ Jul 2030
Phase 3Current
NCT08261252
343 pts·CKD
2023-11→TBD·Recruiting
NCT04395834
491 pts·Obesity
2019-10→2030-07·Completed
834 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-214.3y awayPh3 Readout· Obesity
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2030-07-21 · 4.3y away
Obesity
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08261252 | Phase 3 | CKD | Recruiting | 343 | FEV1 |
| NCT04395834 | Phase 3 | Obesity | Completed | 491 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |